User profiles for Robin Marlow
 | Robin MarlowConsultant in Paediatric Emergency Medicine / Honorary Senior Lecturer Verified email at bristol.ac.uk Cited by 813 |
Severity of Omicron (B. 1.1. 529) and Delta (B. 1.617. 2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom
Background There is an urgent public health need to evaluate disease severity in adults
hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist …
hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist …
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case …
Background On Dec 8, 2020, deployment of the first SARS-CoV-2 vaccination authorised for
UK use (BNT162b2 mRNA vaccine) began, followed by an adenoviral vector vaccine …
UK use (BNT162b2 mRNA vaccine) began, followed by an adenoviral vector vaccine …
Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal
Importance A 4-component meningococcus group B vaccine (4CMenB) is the only vaccine in
use to prevent group B invasive meningococcal disease in young children, but no matched …
use to prevent group B invasive meningococcal disease in young children, but no matched …
Assessing the association between bronchiolitis in infancy and recurrent wheeze: a whole English birth cohort case–control study
The precise association between bronchiolitis and predisposition to childhood wheeze is
unclear. We assessed bronchiolitis aetiology and later wheeze phenotypes in the entire 2007 …
unclear. We assessed bronchiolitis aetiology and later wheeze phenotypes in the entire 2007 …
[HTML][HTML] Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination
…, A Banzhoff, C Azzari, P De Wals, R Marlow… - Journal of Infection, 2021 - Elsevier
Objectives 4CMenB is a broadly protective vaccine against invasive meningococcal capsular
group B disease (MenB IMD). Licensed worldwide based on immunogenicity and safety …
group B disease (MenB IMD). Licensed worldwide based on immunogenicity and safety …
Assessing the effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 vaccination in prevention of hospitalisations in elderly and frail adults: a single centre test …
Background: On 8 th December 2020, deployment of the first vaccine against SARS-CoV-2
authorised for UK use, the mRNA-based vaccine BNT162b2, began, followed by the …
authorised for UK use, the mRNA-based vaccine BNT162b2, began, followed by the …
Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B. 1.617. 2) and Omicron (B …
Background Whilst other studies have reported the effectiveness of mRNA vaccination against
hospitalisation, including emergency department or intensive care admission, few have …
hospitalisation, including emergency department or intensive care admission, few have …
Incidence of community acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: A prospective cohort study
Background The emergence of COVID-19 and public health measures implemented to
reduce SARS-CoV-2 infections have both affected acute lower respiratory tract disease (aLRTD) …
reduce SARS-CoV-2 infections have both affected acute lower respiratory tract disease (aLRTD) …
Relative vaccine effectiveness (rVE) of mRNA COVID-19 boosters in the UK vaccination programme, during the Spring-Summer (monovalent vaccine) and Autumn …
Background Understanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine
formulations against SARS-CoV-2 infection is an urgent public health priority. A precise …
formulations against SARS-CoV-2 infection is an urgent public health priority. A precise …
[HTML][HTML] Assessing the impacts of the first year of rotavirus vaccination in the United Kingdom
The United Kingdom (UK) added rotavirus (RV) vaccine (Rotarix GlaxoSmithKline) to the
national vaccine schedule in July 2013. During the 2012–2014 rotavirus seasons, children …
national vaccine schedule in July 2013. During the 2012–2014 rotavirus seasons, children …